SHARE
 
Peiman Hematti, MD close
6SrNJEnsIXs
Peiman Hematti, MD
 

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Peiman Hematti, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Peiman Hematti joined the Section of Hematology/Bone Marrow Transplantation at the University of Wisconsin-Madison in July 2004 as an Assistant Professor in the Department of Medicine. Dr. Hematti has completed a combined Internal Medicine/Pediatrics residency at the Cleveland Clinic Foundation and then Hematology fellowship at the National Heart, Lung and Blood Institute at the National Institutes of Health. His clinical interests are in inpatient care of hematopoietic stem cell transplant patients. He is the director of the clinical hematopoietic cell processing laboratory, and in that capacity oversees all the peripheral blood stem cell collections from the patients and processing of their products.

Specialties

Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine
Department of Pediatrics

Professional Certifications and Education

Board Certification Hematology
Internal Medicine
Pediatrics
Fellowship National Institutes of Health, Bethesda, MD
Residency Cleveland Clinic Foundation, Cleveland, OH
Internship Cleveland Clinic Foundation, Cleveland, OH
Medical School Tehran University of Medical Sciences, Tehran, Iran

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Dr. Hematti runs an active basic research lab with the goal of developing methods for ex vivo generation and expansion of hematopoietic stem cells. His clinical research interest is in using novel mobilization agents for collection of peripheral blood stem cells.


PubMed Articles
Frigault MJ Nikiforow S Mansour MK Hu ZH Horowitz MM Riches ML Hematti P Turtle CJ Zhang MJ Perales MA Pasquini MC Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood . 2020 Jul 2;136(1):137-139
[PubMed ID: 32457999]
Hess NJ Hudson AW Hematti P Gumperz JE Early T Cell Activation Metrics Predict Graft-versus-Host Disease in a Humanized Mouse Model of Hematopoietic Stem Cell Transplantation. J Immunol . 2020 Jul 1;205(1):272-281
[PubMed ID: 32444392]
Liao R Zheng Y Liu X Zhang Y Seim G Tanimura N Wilson GM Hematti P Coon JJ Fan J Xu J Keles S Bresnick EH Discovering How Heme Controls Genome Function Through Heme-omics. Cell Rep . 2020 Jun 30;31(13):107832
[PubMed ID: 32610133]
Mehta RS Holtan SG Wang T Hemmer MT Spellman SR Arora M Couriel DR Alousi AM Pidala J Abdel-Azim H Agrawal V Ahmed I Al-Homsi AS Aljurf M Antin JH Askar M Auletta JJ Bhatt VR Chee L Chhabra S Daly A DeFilipp Z Gajewski J Gale RP Gergis U Hematti P Hildebrandt GC Hogan WJ Inamoto Y Martino R Majhail NS Marks DI Nishihori T Olsson RF Pawarode A Diaz MA Prestidge T Rangarajan HG Ringden O Saad A Savani BN Schoemans H Seo S Schultz KR Solh M Spitzer T Storek J Teshima T Verdonck LF Wirk B Yared JA Cahn JY Weisdorf DJ Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol . 2020 Jun 20;38(18):2062-2076
[PubMed ID: 32364845]
Hsu JW Shaw BE Kim S Logan BR Sees JA Confer DL Pulsipher MA Shah N Switzer GE Abidi MH Ahmed IA Anderlini PN Bredeson C Chhabra S Dandoy CE Diaz MA Farhadfar N Ganguly S Gergis U Hale GA Hematti P Kamble RT Kasow KA Lazarus HM Liesveld JL Murthy HS Olsson RF Savani BN Schears R Seo S Solh M Spitzer T Steinberg A Sugrue M Warkentin P Wingard JR Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. Biol Blood Marrow Transplant . 2020 Jun;26(6):1210-1217
[PubMed ID: 32088366]
Epperla N Li A Logan B Fretham C Chhabra S Aljurf M Chee L Copelan E Freytes CO Hematti P Lazarus HM Litzow M Nishihori T Olsson RF Prestidge T Saber W Wirk B Yared JA Loren A Pasquini M Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol . 2020 Jun;189(6):1171-1181
[PubMed ID: 32124435]
Im A Rashidi A Wang T Hemmer M MacMillan ML Pidala J Jagasia M Pavletic S Majhail NS Weisdorf D Abdel-Azim H Agrawal V Al-Homsi AS Aljurf M Askar M Auletta JJ Bashey A Beitinjaneh A Bhatt VR Byrne M Cahn JY Cairo M Castillo P Cerny J Chhabra S Choe H Ciurea S Daly A Perez MAD Farhadfar N Gadalla SM Gale R Ganguly S Gergis U Hanna R Hematti P Herzig R Hildebrandt GC Lad DP Lee C Lehmann L Lekakis L Kamble RT Kharfan-Dabaja MA Khandelwal P Martino R Murthy HS Nishihori T O'Brien TA Olsson RF Patel SS Perales MA Prestidge T Qayed M Romee R Schoemans H Seo S Sharma A Solh M Strair R Teshima T Urbano-Ispizua A Van der Poel M Vij R Wagner JL William B Wirk B Yared JA Spellman SR Arora M Hamilton BK Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant . 2020 May 17;
[PubMed ID: 32434056]
Jabbehdari S Yazdanpanah G Kanu LN Chen E Kang K Anwar KN Ghassemi M Hematti P Rosenblatt MI Djalilian AR Therapeutic Effects of Lyophilized Conditioned-Medium Derived from Corneal Mesenchymal Stromal Cells on Corneal Epithelial Wound Healing. Curr Eye Res . 2020 May 14;:1-7
[PubMed ID: 32338541]
Kahn JM Brazauskas R Tecca HR Bo-Subait S Buchbinder D Battiwala M Flowers MED Savani BN Phelan R Broglie L Abraham AA Keating AK Daly A Wirk B George B Alter BP Ustun C Freytes CO Beitinjaneh AM Duncan C Copelan E Hildebrandt GC Murthy HS Lazarus HM Auletta JJ Myers KC Williams KM Page KM Vrooman LM Norkin M Byrne M Diaz MA Kamani N Bhatt NS Rezvani A Farhadfar N Mehta PA Hematti P Shaw PJ Kamble RT Schears R Olsson RF Hayashi RJ Gale RP Mayo SJ Chhabra S Rotz SJ Badawy SM Ganguly S Pavletic S Nishihori T Prestidge T Agrawal V Hogan WJ Inamoto Y Shaw BE Satwani P Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv . 2020 May 12;4(9):2084-2094
[PubMed ID: 32396620]
Lee CJ Kim S Tecca HR Bo-Subait S Phelan R Brazauskas R Buchbinder D Hamilton BK Battiwalla M Majhail NS Lazarus HM Shaw PJ Marks DI Litzow MR Chhabra S Inamoto Y DeFilipp Z Hildebrandt GC Olsson RF Kasow KA Liesveld JL Rotz SJ Badawy SM Bhatt NS Yared JA Page KM Arellano ML Kent M Farhadfar N Seo S Hematti P Freytes CO Rovó A Ganguly S Nathan S Burns L Shaw BE Muffly LS Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv . 2020 Mar 24;4(6):983-992
[PubMed ID: 32168378]
Farhadfar N Hsu JW Logan BR Sees JA Chitphakdithai P Sugrue MW Abdel-Azim H Anderlini PN Bredeson C Chhabra S Diaz MA Ganguly S Hematti P Kamble RT Kasow KA Lazarus HM Lynch DK Murthy HS Olsson RF Papari M Przepiorka D Savani BN Schears R Seo S Solh MM Spitzer T Yared JA Pulsipher MA Shah NN Switzer GE Confer DL Shaw BE Wingard JR Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. Blood Adv . 2020 Feb 25;4(4):706-716
[PubMed ID: 32092138]
Zinter MS Logan BR Fretham C Sapru A Abraham A Aljurf MD Arnold SD Artz A Auletta JJ Chhabra S Copelan E Duncan C Gale RP Guinan E Hematti P Keating AK Marks DI Olsson R Savani BN Ustun C Williams KM Pasquini MC Dvorak CC Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biol Blood Marrow Transplant . 2020 Feb;26(2):333-342
[PubMed ID: 31563573]
Dandoy CE Kim S Chen M Ahn KW Ardura MI Brown V Chhabra S Diaz MA Dvorak C Farhadfar N Flagg A Ganguly S Hale GA Hashmi SK Hematti P Martino R Nishihori T Nusrat R Olsson RF Rotz SJ Sung AD Perales MA Lindemans CA Komanduri KV Riches ML Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Netw Open . 2020 Jan 3;3(1):e1918668
[PubMed ID: 31913492]
Fontana G Martin HL Lee JS Schill K Hematti P Murphy WL Mineral-Coated Microparticles Enhance mRNA-Based Transfection of Human Bone Marrow Cells. Mol Ther Nucleic Acids . 2019 Dec 6;18:455-464
[PubMed ID: 31655263]
Sabloff M Chhabra S Wang T Fretham C Kekre N Abraham A Adekola K Auletta JJ Barker C Beitinjaneh AM Bredeson C Cahn JY Diaz MA Freytes C Gale RP Ganguly S Gergis U Guinan E Hamilton BK Hashmi S Hematti P Hildebrandt G Holmberg L Hong S Lazarus HM Martino R Muffly L Nishihori T Perales MA Yared J Mineishi S Stadtmauer EA Pasquini MC Loren AW Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant . 2019 Dec;25(12):2398-2407
[PubMed ID: 31473319]
Kink JA Forsberg MH Reshetylo S Besharat S Childs CJ Pederson JD Gendron-Fitzpatrick A Graham M Bates PD Schmuck EG Raval A Hematti P Capitini CM Macrophages Educated with Exosomes from Primed Mesenchymal Stem Cells Treat Acute Radiation Syndrome by Promoting Hematopoietic Recovery. Biol Blood Marrow Transplant . 2019 Nov;25(11):2124-2133
[PubMed ID: 31394269]
Solomon SR St Martin A Shah NN Fatobene G Al Malki MM Ballen KK Bashey A Bejanyan N Bolaños Meade J Brunstein CG DeFilipp Z Champlin RE Fuchs EJ Hamadani M Hematti P Kanakry CG McGuirk JP McNiece IK Ciurea SO Pasquini MC Rocha V Romee R Patel SS Vasu S Waller EK Wingard JR Zhang MJ Eapen M Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood Adv . 2019 Oct 8;3(19):2836-2844
[PubMed ID: 31582392]
Lung DK Warrick JW Hematti P Callander NS Mark CJ Miyamoto S Alarid ET Bone Marrow Stromal Cells Transcriptionally Repress ESR1 but Cannot Overcome Constitutive ESR1 Mutant Activity. Endocrinology . 2019 Oct 1;160(10):2427-2440
[PubMed ID: 31504407]
Dhakal B Pagenkopf A Mushtaq MU Cunningham AM Flietner E Morrow Z Papadas A Hope C Leith C Hematti P Hari P Callander NS Asimakopoulos F Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leuk Lymphoma . 2019 Oct;60(10):2558-2562
[PubMed ID: 30845856]
Kaufman DB Hematti P Golden RN Immunosuppression-Free Kidney Transplantation: Advancing New Treatments by Building on Our Past Foundations. WMJ . 2019 Oct;118(3):146-147
[PubMed ID: 31682753]